Oral semaglutide: Wegovy® pill arrives
The FDA has approved oral semaglutide 25mg for weight management, with early 2026 anticipated as the launch window in the United States. This is the first oral GLP-1 receptor agonist licensed for obesity treatment.
Results from the Phase III OASIS-4 trial show meaningful reductions in body weight compared with placebo, alongside improvements in cardiometabolic markers. The oral pill is designed to survive digestion and deliver similar effects to injectable semaglutide.
Higher-dose semaglutide: Wegovy® 7.2mg
A 7.2mg once-weekly semaglutide injection is now available. Clinical studies suggest greater weight loss than lower doses, with safety and tolerability broadly comparable to the established 2.4mg dose. Careful dose titration and individual assessment remain key.
Emerging GLP-1 and multi-agonist therapies
Dual Agonists
Medications like Mounjaro (tirzepatide) combine GLP-1 and GIP agonism and are already available in some regions.
Oral GLP-1 Pills from Other Companies
Other pharmaceutical companies, including Eli Lilly, are developing oral GLP-1 therapies. Some are in advanced clinical trials, but approval timelines and availability are still uncertain.
Triple-Agonist Therapies (Triple-G)
Research continues into medications targeting three hormonal pathways simultaneously: GLP-1, GIP, and glucagon receptors, such as Retatrutide. Sometimes referred to in media as “triple-G,” these therapies are still being studied. Early data suggest strong weight-loss potential, but longer-term safety and efficacy data are still needed.
What this means for patients
- Patients now have a broader range of medical treatment options.
- Treatment decisions should still be based on individual response, medical history, and safety.
- Lifestyle support — including diet, activity, and behavioural change — remains essential.
Looking ahead
2026 is likely to bring more flexibility in obesity treatment, with oral GLP-1 pills, higher-dose injectables, and multi-agonist therapies expanding options. Clinicians and patients should stay updated as new evidence and approvals emerge.
Key takeaways
- Oral semaglutide (Wegovy® pill) expected in early 2026 in the US.
- Higher-dose semaglutide (7.2mg) may provide an additional injectable option.
- New dual and triple-agonist therapies are in development, with availability dates expected to be clarified as evidence matures.
- Personalised treatment decisions remain essential, alongside lifestyle support.
Disclaimer & summary
This article is for information only and does not replace personal medical advice. Availability and approvals vary by country. Always speak to a qualified healthcare professional before starting or changing treatment.
2026 is shaping up to be an important year in weight management. Oral semaglutide, higher-dose injections, and emerging dual and triple-agonist medicines may expand options for adults living with obesity. Clinical guidance remains essential for safe, effective, and personalised care.
